Figure 1

Study timeline. Individuals enrolled in the SJTRC study in early 2020. Upon enrollment, a blood sample and demographic information were collected followed by collection of weekly nasopharyngeal swabs as a part of a SARS-CoV-2 employee asymptomatic screening program. If someone tested positive prior to becoming vaccinated, they were included in the infected cohort (N = 48). After testing positive, nasal swabs and plasma were collected during the acute, early convalescent, late convalescent, post convalescent, and late post convalescent phases of infection. If individuals managed to remain SARS-CoV-2 negative before receiving two doses of the Pfizer mRNA BNT162b2 vaccine, they were included in the vaccination cohort (N = 26). These individuals also provided nasal swabs and plasma at 22–56 days post vaccination (dpv), 57–89 dpv, 90–180 dpv, and > 180 dpv.